Literature DB >> 28367678

Comparing costs of illness of multiple sclerosis in three different years: A population-based study.

Hanna Gyllensten1, Michael Wiberg2, Kristina Alexanderson3, Emilie Friberg3, Jan Hillert3, Petter Tinghög4.   

Abstract

BACKGROUND: Little is known about changes in the costs of illness (COI) among multiple sclerosis (MS) patients during recent years.
OBJECTIVES: To compare the COI among MS patients and matched controls in 2006, 2009, and 2012, respectively, indicating the costs attributable to the MS disease.
METHODS: Three cross-sectional datasets were analyzed, including all MS patients in Sweden aged 20-60 years and five matched controls for each of them. The analyses were based on 10,531 MS patients and 52,655 matched controls for 2006, 11,722 and 58,610 individuals for 2009, and 12,789 and 63,945 for 2012. Nationwide registers, including prescription drug use, specialized healthcare, sick leave, and disability pension, were linked to estimate the prevalence-based COI.
RESULTS: Adjusted for inflation, the average difference in COI between MS patients and matched controls were Swedish Krona (SEK) 243,751 (95% confidence interval: SEK 239,171-248,331) in 2006, SEK 238,971 (SEK 234,516-243,426) in 2009, and SEK 225,923 (SEK 221,630-230,218) in 2012. The difference in indirect costs were SEK 170,502 (SEK 166,478-174,525) in 2006, SEK 158,839 (SEK 154,953-162,726) in 2009, and SEK 141,280 (SEK 137,601-144,960) in 2012.
CONCLUSION: The inflation-adjusted COI of MS patients was lower in 2012 than in 2006, in particular regarding indirect costs.

Entities:  

Keywords:  Multiple sclerosis; cost of illness; drug costs; healthcare costs; registries; sick leave; time trends

Mesh:

Year:  2017        PMID: 28367678     DOI: 10.1177/1352458517702549

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

1.  Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.

Authors:  Omid Beiki; Paolo Frumento; Matteo Bottai; Ali Manouchehrinia; Jan Hillert
Journal:  JAMA Neurol       Date:  2019-06-01       Impact factor: 18.302

2.  Cost-of-illness trajectories among people with multiple sclerosis by comorbidity: A register-based prospective study in Sweden.

Authors:  Greta Bütepage; Ahmed Esawi; Kristina Alexanderson; Emilie Friberg; Chantelle Murley; Jan Hillert; Korinna Karampampa
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-10-23

3.  Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Authors:  Peter Alping; Fredrik Piehl; Annette Langer-Gould; Thomas Frisell
Journal:  Epidemiology       Date:  2019-03       Impact factor: 4.822

4.  Earnings among people with multiple sclerosis compared to references, in total and by educational level and type of occupation: a population-based cohort study at different points in time.

Authors:  Michael Wiberg; Chantelle Murley; Petter Tinghög; Kristina Alexanderson; Edward Palmer; Jan Hillert; Magnus Stenbeck; Emilie Friberg
Journal:  BMJ Open       Date:  2019-07-11       Impact factor: 2.692

5.  Comparison of employment among people with Multiple Sclerosis across Europe.

Authors:  David Ellenberger; Tina Parciak; Waldemar Brola; Jan Hillert; Rod Middleton; Alexander Stahmann; Christoph Thalheim; Peter Flachenecker
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-04-27

6.  Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group.

Authors:  Chantelle Murley; Petter Tinghög; Kristina Alexanderson; Jan Hillert; Emilie Friberg; Korinna Karampampa
Journal:  Pharmacoeconomics       Date:  2021-05-10       Impact factor: 4.981

7.  Trajectories of disposable income among people of working ages diagnosed with multiple sclerosis: a nationwide register-based cohort study in Sweden 7 years before to 4 years after diagnosis with a population-based reference group.

Authors:  Chantelle Murley; Olof Mogard; Michael Wiberg; Kristina Alexanderson; Korinna Karampampa; Emilie Friberg; Petter Tinghög
Journal:  BMJ Open       Date:  2018-05-09       Impact factor: 2.692

8.  Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany.

Authors:  Sabrina Müller; Tobias Heidler; Andreas Fuchs; Andreas Pfaff; Kathrin Ernst; Gunter Ladinek; Thomas Wilke
Journal:  Neurol Ther       Date:  2019-12-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.